ArticleMicrosurgery2026
Vasopressor Use in Free Flap Reconstruction: A Multicenter Propensity-Matched Analysis of Outcomes.
Article in Microsurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe use of intraoperative vasopressors during microvascular free flap reconstruction remains controversial due to concerns regarding vasoconstriction and impaired flap perfusion. This study evaluates the association between vasopressor use and postoperative outcomes across a large, multicenter cohort.
methodsA retrospective cohort study was performed using the TriNetX Collaborative Network. Adult patients undergoing free flap reconstruction were identified and stratified by intraoperative vasopressor exposure. Propensity score matching (1:1) was used to balance baseline characteristics. Outcomes within 90 days included flap-related complications, wound complications, reoperation, and mortality. Subgroup analyses were conducted by flap type and vasopressor agent.
resultsA total of 43,157 patients were identified, with 17,970 matched pairs included. Overall vasopressor use was associated with increased risks of infection (RR 1.10, 95% CI 1.05-1.15; p < 0.01) and wound dehiscence (RR 1.09, 95% CI 1.02-1.15; p = 0.01), and decreased rates of debridement (RR 0.84, 95% CI 0.78-0.90; p < 0.01). Phenylephrine demonstrated the most consistent association with adverse wound outcomes, including infection (RR 1.17, 95% CI 1.10-1.24; p < 0.01), dehiscence (RR 1.15, 95% CI 1.06-1.24; p < 0.01), skin graft failure (RR 1.17, 95% CI 1.03-1.33; p = 0.02), and anastomotic revision (RR 1.29, 95% CI 1.02-1.65; p = 0.04). Breast reconstructions showed higher complication rates with vasopressor exposure, extremity reconstructions demonstrated minimal differences, and head and neck reconstructions showed increased infection, skin graft failure, and mortality. No consistent increase in flap failure or reoperation rates was observed.
conclusionsIntraoperative vasopressor use is associated with modest increases in select postoperative complications, with variability by agent and flap type. Phenylephrine may carry higher risk, while other agents demonstrate more neutral effects. These findings support a selective, context-dependent approach to vasopressor use during free flap reconstruction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.